Welcome

​​​DepYmed

DepYmed Inc., is a New York based cancer therapeutic development company. DepYmed is developing potent inhibitors of the enzyme PTP1B (protein tyrosine phosphatase 1B) with its current lead compound, MSI-1436C, in clinical development as a therapeutic candidate for HER2-positive breast cancer. DepYmed continues to develop the next generation of more potent PTP1B inhibitors / analogs which are currently in preclinical development in collaboration with Cold Spring Harbor Laboratory and continues to explore additional indications that may benefit from using PTP1B inhibitors as therapeutic agents.